{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:24:14Z","timestamp":1772119454439,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>This study aimed to investigate the clinical efficacy of tapentadol extended-release (ER) on pain control and the quality of life (QoL) of patients with moderate to severe chronic cancer pain in clinical practice in Korea.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this prospective, open-label, multicenter trial, patients with sustained cancer pain as well as chronic pain, who were or were not using other analgesics were enrolled. Thirteen centers recorded a total of 752 patients during the 6-month observation period, based on the tapentadol ER dose and tolerability, prior and concomitant analgesic treatment, pain intensity, type of pain, adverse effects, and clinical global impression change (CGI-C). Of those 752 patients, 688 were enrolled, and 650 completed the study for efficacy and adverse drug reactions; among them, 349 were cancer patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tapentadol ER significantly reduced the mean pain intensity including neuropathic pain during the observation period by 2.9 points (from a mean 7\u2009\u00b1\u20090.87 to 4.1\u2009\u00b1\u20092.02). Furthermore, QoL was observed to be significantly improved based on the CGI-C, an objective measure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study showed that tapentadol ER was effective for treating patients with moderate to severe cancer pain and neuropathic pain, and therefore it significantly improved the patients\u2019 QoL.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00520-022-06992-w","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T05:03:14Z","timestamp":1649912594000},"page":"6103-6112","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A prospective, multicenter, open-label study of the clinical efficacy of tapentadol extended-release in the treatment of cancer-related pain and improvement in the quality of life of opioid-na\u00efve or opioid-resistant patients"],"prefix":"10.1007","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2017-4994","authenticated-orcid":false,"given":"Ji Yoon","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6979-5812","authenticated-orcid":false,"given":"Hong Jae","family":"Chon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3525-8154","authenticated-orcid":false,"given":"Young Jin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9682-7955","authenticated-orcid":false,"given":"Sang Eun","family":"Yeon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6542-2963","authenticated-orcid":false,"given":"Seok Young","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0462-2512","authenticated-orcid":false,"given":"Kyung Hee","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"6992_CR1","doi-asserted-by":"publisher","first-page":"2236","DOI":"10.1016\/S0140-6736(11)60236-5","volume":"377","author":"RK Portenoy","year":"2011","unstructured":"Portenoy RK (2011) Treatment of cancer pain. Lancet 377:2236\u20132247","journal-title":"Lancet"},{"key":"6992_CR2","doi-asserted-by":"publisher","first-page":"379","DOI":"10.36076\/ppj.2013\/16\/379","volume":"16","author":"N Te Boveldt","year":"2013","unstructured":"Te Boveldt N, Vernooij-Dassen M, Burger N, Ijsseldijk M, Vissers K, Engels Y (2013) Pain and its interference with daily activities in medical oncology outpatients. Pain Physician 16:379\u2013389","journal-title":"Pain Physician"},{"key":"6992_CR3","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.jpainsymman.2015.12.340","volume":"51","author":"MH van den Beuken-van Everdingen","year":"2016","unstructured":"van den Beuken-van Everdingen MH, Hochstenbach LM, Joosten EA, Tjan-Heijnen VC, Janssen DJ (2016) Update on prevalence of pain in patients with cancer: systematic review and meta-analysis. J Pain Symptom Manage 51:1070-1090 e9","journal-title":"J Pain Symptom Manage"},{"key":"6992_CR4","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1093\/annonc\/mdn419","volume":"19","author":"S Deandrea","year":"2008","unstructured":"Deandrea S, Montanari M, Moja L, Apolone G (2008) Prevalence of undertreatment in cancer pain. A review of published literature. Ann Oncol 19:1985\u20131991","journal-title":"Ann Oncol"},{"key":"6992_CR5","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1093\/annonc\/mdp001","volume":"20","author":"H Breivik","year":"2009","unstructured":"Breivik H, Cherny N, Collett B et al (2009) Cancer-related pain: a pan-European survey of prevalence, treatment, and patient attitudes. Ann Oncol 20:1420\u20131433","journal-title":"Ann Oncol"},{"key":"6992_CR6","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1093\/annonc\/mdm056","volume":"18","author":"MH van den Beuken-van Everdingen","year":"2007","unstructured":"van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J (2007) Prevalence of pain in patients with cancer: a systematic review of the past 40 years. Ann Oncol 18:1437\u20131449","journal-title":"Ann Oncol"},{"key":"6992_CR7","doi-asserted-by":"publisher","first-page":"510","DOI":"10.3390\/cancers11040510","volume":"11","author":"A Caraceni","year":"2019","unstructured":"Caraceni A, Shkodra M (2019) Cancer pain assessment and classification. Cancers (Basel) 11:510","journal-title":"Cancers (Basel)"},{"key":"6992_CR8","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1016\/j.pain.2011.10.028","volume":"153","author":"MI Bennett","year":"2012","unstructured":"Bennett MI, Rayment C, Hjermstad M, Aass N, Caraceni A, Kaasa S (2012) Prevalence and aetiology of neuropathic pain in cancer patients: a systematic review. Pain 153:359\u2013365","journal-title":"Pain"},{"key":"6992_CR9","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1016\/S0959-8049(02)00229-0","volume":"38","author":"G Cavaletti","year":"2002","unstructured":"Cavaletti G, Zanna C (2002) Current status and future prospects for the treatment of chemotherapy-induced peripheral neurotoxicity. Eur J Cancer 38:1832\u20131837","journal-title":"Eur J Cancer"},{"key":"6992_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1529-8027.2008.00156.x","volume":"13","author":"AJ Windebank","year":"2008","unstructured":"Windebank AJ, Grisold W (2008) Chemotherapy-induced neuropathy. J Peripher Nerv Syst 13:27\u201346","journal-title":"J Peripher Nerv Syst"},{"key":"6992_CR11","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1111\/papr.12018","volume":"13","author":"V Piano","year":"2013","unstructured":"Piano V, Verhagen S, Schalkwijk A et al (2013) Diagnosing neuropathic pain in patients with cancer: comparative analysis of recommendations in national guidelines from European countries. Pain Pract 13:433\u2013439","journal-title":"Pain Pract"},{"key":"6992_CR12","doi-asserted-by":"publisher","first-page":"e58","DOI":"10.1016\/S1470-2045(12)70040-2","volume":"13","author":"A Caraceni","year":"2012","unstructured":"Caraceni A, Hanks G, Kaasa S et al (2012) Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. Lancet Oncol 13:e58-68","journal-title":"Lancet Oncol"},{"key":"6992_CR13","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1177\/0269216312464408","volume":"27","author":"C Rayment","year":"2013","unstructured":"Rayment C, Hjermstad MJ, Aass N et al (2013) Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med 27:714\u2013721","journal-title":"Palliat Med"},{"key":"6992_CR14","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","volume":"29","author":"M Fallon","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F et al (2018) Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol 29:iv166\u2013iv191","journal-title":"Ann Oncol"},{"key":"6992_CR15","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1111\/j.1468-1331.2010.02999.x","volume":"17","author":"N Attal","year":"2010","unstructured":"Attal N, Cruccu G, Baron R et al (2010) EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol 17:1113-e88","journal-title":"Eur J Neurol"},{"key":"6992_CR16","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.4065\/mcp.2009.0649","volume":"85","author":"RH Dworkin","year":"2010","unstructured":"Dworkin RH, O\u2019Connor AB, Audette J et al (2010) Recommendations for the pharmacological management of neuropathic pain: an overview and literature update. Mayo Clin Proc 85:S3-14","journal-title":"Mayo Clin Proc"},{"key":"6992_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.3344\/kjp.2010.23.2.99","volume":"23","author":"HJ Park","year":"2010","unstructured":"Park HJ, Moon DE (2010) Pharmacologic management of chronic pain. Korean J Pain 23:99\u2013108","journal-title":"Korean J Pain"},{"key":"6992_CR18","first-page":"18","volume":"70","author":"AJ Beijers","year":"2012","unstructured":"Beijers AJ, Jongen JL, Vreugdenhil G (2012) Chemotherapy-induced neurotoxicity: the value of neuroprotective strategies. Neth J Med 70:18\u201325","journal-title":"Neth J Med"},{"key":"6992_CR19","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1200\/JCO.2013.52.0536","volume":"32","author":"CL Loprinzi","year":"2014","unstructured":"Loprinzi CL, Qin R, Dakhil SR et al (2014) Phase III randomized, placebo-controlled, double-blind study of intravenous calcium and magnesium to prevent oxaliplatin-induced sensory neurotoxicity (N08CB\/Alliance). J Clin Oncol 32:997\u20131005","journal-title":"J Clin Oncol"},{"key":"6992_CR20","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1124\/jpet.107.126052","volume":"323","author":"TM Tzschentke","year":"2007","unstructured":"Tzschentke TM, Christoph T, Kogel B et al (2007) (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist\/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther 323:265\u2013276","journal-title":"J Pharmacol Exp Ther"},{"key":"6992_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1016\/j.ejpain.2010.06.017","volume":"14","author":"HG Kress","year":"2010","unstructured":"Kress HG (2010) Tapentadol and its two mechanisms of action: is there a new pharmacological class of centrally-acting analgesics on the horizon? Eur J Pain 14:781\u2013783","journal-title":"Eur J Pain"},{"key":"6992_CR22","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1185\/03007995.2012.739151","volume":"28","author":"S Mercadante","year":"2012","unstructured":"Mercadante S, Porzio G, Ferrera P et al (2012) Tapentadol in cancer pain management: a prospective open-label study. Curr Med Res Opin 28:1775\u20131779","journal-title":"Curr Med Res Opin"},{"key":"6992_CR23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1185\/03007995.2013.831816","volume":"29","author":"K Imanaka","year":"2013","unstructured":"Imanaka K, Tominaga Y, Etropolski M et al (2013) Efficacy and safety of oral tapentadol extended-release in Japanese and Korean patients with moderate to severe, chronic malignant tumor-related pain. Curr Med Res Opin 29:1399\u20131409","journal-title":"Curr Med Res Opin"},{"key":"6992_CR24","doi-asserted-by":"publisher","first-page":"329","DOI":"10.36076\/ppj.2014\/17\/329","volume":"17","author":"HG Kress","year":"2014","unstructured":"Kress HG, Koch ED, Kosturski H et al (2014) Tapentadol prolonged release for managing moderate to severe, chronic malignant tumor-related pain. Pain Physician 17:329\u2013343","journal-title":"Pain Physician"},{"key":"6992_CR25","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1185\/03007995.2014.934793","volume":"30","author":"S Mercadante","year":"2014","unstructured":"Mercadante S, Porzio G, Adile C et al (2014) Tapentadol at medium to high doses in patients previously receiving strong opioids for the management of cancer pain. Curr Med Res Opin 30:2063\u20132068","journal-title":"Curr Med Res Opin"},{"key":"6992_CR26","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1007\/s12325-017-0654-0","volume":"35","author":"A Stollenwerk","year":"2018","unstructured":"Stollenwerk A, Sohns M, Heisig F, Elling C, von Zabern D (2018) Review of post-marketing safety data on tapentadol, a centrally acting analgesic. Adv Ther 35:12\u201330","journal-title":"Adv Ther"},{"key":"6992_CR27","doi-asserted-by":"publisher","first-page":"173","DOI":"10.2217\/pmt-2020-0084","volume":"11","author":"CM Ferri","year":"2021","unstructured":"Ferri CM, Natoli S, Sanz-Ayan P et al (2021) Quality of life and functional outcomes with tapentadol prolonged release in chronic musculoskeletal pain: post hoc analysis. Pain Manag 11:173\u2013187","journal-title":"Pain Manag"},{"key":"6992_CR28","unstructured":"Guy W (ed) (1976) ECDEU assessment manual for psychopharmacology. US Department of Heath, Education, and Welfare Public Health Service Alcohol, Drug Abuse, and Mental Health Administration. https:\/\/archive.org\/details\/ecdeuassessmentm1933guyw\/page\/218\/mode\/2up?view=theater. Accessed 21 Oct 2021"},{"key":"6992_CR29","doi-asserted-by":"publisher","first-page":"S73","DOI":"10.1016\/j.jpain.2009.01.258","volume":"10","author":"L Ferguson","year":"2009","unstructured":"Ferguson L, Scheman J (2009) Patient global impression of change scores within the context of a chronic pain rehabilitation program. J Pain 10:S73","journal-title":"J Pain"},{"key":"6992_CR30","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1002\/ejp.1378","volume":"23","author":"S Perrot","year":"2019","unstructured":"Perrot S, Lanteri-Minet M (2019) Patients\u2019 global impression of change in the management of peripheral neuropathic pain: clinical relevance and correlations in daily practice. Eur J Pain 23:1117\u20131128","journal-title":"Eur J Pain"},{"key":"6992_CR31","unstructured":"U.S. Food and Drug Administration (2019) Full prescribing information of tapentadol extended-release tablets for oral use. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/200533s020lbl.pdf. Accessed 21 Oct 2021"},{"key":"6992_CR32","unstructured":"Korea Ministry of Food and Drug Safety (2021) Full prescribing information of tapentadol extended-release tablets for oral use. https:\/\/nedrug.mfds.go.kr\/pbp\/CCBBB01\/getItemDetail?itemSeq=201603372 Accessed 21 Oct 2021"},{"key":"6992_CR33","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1111\/j.1600-0447.1983.tb09716.x","volume":"67","author":"AS Zigmond","year":"1983","unstructured":"Zigmond AS, Snaith RP (1983) The hospital anxiety and depression scale. Acta Psychiatr Scand 67:361\u2013370","journal-title":"Acta Psychiatr Scand"},{"key":"6992_CR34","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/00005650-199603000-00003","volume":"34","author":"J Ware Jr","year":"1996","unstructured":"Ware J Jr, Kosinski M, Keller SD (1996) A 12-item short-form health survey: construction of scales and preliminary tests of reliability and validity. Med Care 34:220\u2013233","journal-title":"Med Care"},{"key":"6992_CR35","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s004820050216","volume":"13","author":"HD Basler","year":"1999","unstructured":"Basler HD (1999) The Marburg questionnaire on habitual health findings\u2013a study on patients with chronic pain. Schmerz 13:385\u2013391","journal-title":"Schmerz"},{"key":"6992_CR36","first-page":"1","volume":"8","author":"A Schikowski","year":"2015","unstructured":"Schikowski A, Krings D, Schwenke K (2015) Tapentadol prolonged release for severe chronic cancer-related pain: effectiveness, tolerability, and influence on quality of life of the patients. J Pain Res 8:1\u20138","journal-title":"J Pain Res"},{"key":"6992_CR37","doi-asserted-by":"publisher","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","volume":"11","author":"R Benyamin","year":"2008","unstructured":"Benyamin R, Trescot AM, Datta S et al (2008) Opioid complications and side effects. Pain Physician 11:S105-120","journal-title":"Pain Physician"},{"key":"6992_CR38","doi-asserted-by":"publisher","first-page":"e2806","DOI":"10.1136\/bmj.e2806","volume":"344","author":"MI Bennett","year":"2012","unstructured":"Bennett MI, Graham J, Schmidt-Hansen M, Prettyjohns M, Arnold S, Guideline Development Group (2012) Prescribing strong opioids for pain in adult palliative care: summary of NICE guidance. BMJ 344:e2806","journal-title":"BMJ"},{"key":"6992_CR39","doi-asserted-by":"publisher","first-page":"155","DOI":"10.5001\/omj.2011.38","volume":"26","author":"B Jimmy","year":"2011","unstructured":"Jimmy B, Jose J (2011) Patient medication adherence: measures in daily practice. Oman Med J 26:155\u2013159","journal-title":"Oman Med J"},{"key":"6992_CR40","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1007\/s10072-017-3035-1","volume":"38","author":"E Galie","year":"2017","unstructured":"Galie E, Villani V, Terrenato I, Pace A (2017) Tapentadol in neuropathic pain cancer patients: a prospective open-label study. Neurol Sci 38:1747\u20131752","journal-title":"Neurol Sci"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06992-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-022-06992-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-022-06992-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,5,26]],"date-time":"2022-05-26T05:32:28Z","timestamp":1653543148000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-022-06992-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":40,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["6992"],"URL":"https:\/\/doi.org\/10.1007\/s00520-022-06992-w","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-1081101\/v1","asserted-by":"object"}]},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"assertion":[{"value":"16 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki, and the study protocol was approved by the respective Institutional Review Board of each center.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The included patients signed an informed consent form for the use of personal information in connection with post-marketing surveillance.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Ji Yoon Jung, Young Jin Choi, Kyung Hee Lee have no conflicts of interest to declare. Hong Jae Chon has received honoraria from Eisai, Roche, Bayer, ONO, MSD, BMS, Celgene, Sanofi, Servier, AstraZeneca, Sillajen, Menarini, GreenCross Cell, Boryung Pharmaceuticals, and Dong-A ST, and has received research grants from Roche, Dong-A ST, Boryung Pharmaceuticals. Sang Eun Yeon and SeokYoung Choi are employees of Janssen Korea Ltd.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}